Browse the evidence

Obesity in IBD patients is associated with altered pharmacokinetics of biological therapies, leading to faster drug clearance, lower trough concentrations, and potentially reduced treatment efficacy.

If you take biological injections for IBD and are obese, your body might process the drug faster than a lean person's, making it less effective. You should discuss this with your doctor. They might monitor your drug levels more closely or adjust your dose to ensure you get the full benefit of the treatment.

Sarcopenic obesity (high fat mass combined with low muscle mass and function) is a distinct and high-risk phenotype in chronic liver disease (CLD) and IBD, associated with worse prognosis, higher mortality, and increased surgical complications compared to obesity alone or sarcopenia alone.

For people with liver disease or IBD, being obese is risky, but losing muscle makes it much worse. This combination, called 'sarcopenic obesity,' leads to higher death rates and surgery complications. You need to check your muscle mass, not just your weight. If you are losing weight, make sure it's fat, not muscle.

Semaglutide (2.4 mg once weekly) promotes adipose tissue browning and mitochondrial biogenesis via the AMPK/SIRT1/PGC1α/UCP1 axis, enhancing energy expenditure and thermogenesis, although this mechanism is primarily established in preclinical rodent models rather than confirmed in humans.

Semaglutide 2.4mg weekly leads to ~15% weight loss. While it likely works partly by boosting metabolism (browning fat) via complex hormonal pathways seen in animals, the primary driver for you is reduced appetite. Do not rely on the 'browning' mechanism to explain your results; focus on the proven appetite suppression.

GLP-1 receptor agonists (GLP-1RAs) may reduce the severity of Obstructive Sleep Apnoea (OSA) as measured by the Apnoea-Hypopnoea Index (AHI), primarily through weight loss mechanisms, though evidence quality is currently low and results are conflicting.

If you have OSA and are considering GLP-1RAs (like semaglutide or liraglutide), expect a modest improvement in sleep breathing (AHI) rather than a cure. The benefit is largely tied to weight loss. Do not stop using your CPAP machine unless your doctor advises it, as CPAP is currently more effective. Be prepared for potential stomach side effects, which are common but often subside. The evidence is not yet strong enough to make this a standard first-line treatment for OSA alone.

Current evidence does not support a definitive superiority of pre- versus post-exercise creatine timing for muscle creatine loading or performance gains, as existing studies suffer from methodological limitations and conflicting results.

Do not stress about whether you take creatine before or after your workout. The current scientific consensus is that there is no definitive advantage to either timing. Focus on taking your daily dose (e.g., 3-5g) consistently every day to saturate muscle stores, rather than trying to optimize the timing relative to your exercise session.

Dual and triple incretin receptor agonists (e.g., tirzepatide, retatrutide) show potential for greater cardiovascular risk factor reduction than single GLP-1RAs, though definitive cardiovascular outcome trial results are pending.

Newer multi-incretin agonists (like tirzepatide) are showing superior improvements in blood sugar, weight, and blood pressure compared to single GLP-1RAs. While their specific impact on heart attacks and strokes is still being studied, they represent a promising next step for cardiovascular risk reduction in diabetes.

Sleeve gastrectomy (SG) combined with a left ventricular assist device (LVAD) serves as a feasible and effective pathway to cardiac transplantation in morbidly obese patients with end-stage heart failure.

If you have severe heart failure and are too heavy for a heart transplant, getting an LVAD (heart pump) and sleeve gastrectomy (stomach reduction) together is a viable medical pathway. This combination can significantly reduce your weight and make you eligible for a transplant, which was previously impossible due to your size. This requires specialized surgical care.

Resistance exercise-induced lactate accumulation may promote skeletal muscle hypertrophy through multiple mechanisms including lactate-stimulated testosterone production, histone lactylation, and activation of satellite cell pathways via GPR81/ERK1/2 signaling, although direct evidence in humans is currently insufficient.

While mechanical tension is king, incorporating training styles that generate high lactate (e.g., higher reps, shorter rest) may offer additional hypertrophic benefits via metabolic signaling. However, do not rely on this as a primary driver, as human evidence is currently weak compared to mechanical load.

Energy restriction is not supported by scientific evidence for improving glycemic control in Japanese patients with type 2 diabetes.

Current evidence does not support energy restriction as an effective standalone strategy for improving blood sugar in Japanese patients with type 2 diabetes, as studies show little to no benefit compared to other approaches.

A single-administration self-boosting microneedle patch delivering semaglutide sustains therapeutic plasma levels and induces weight loss in rats for one month, effectively simulating four separate weekly subcutaneous injections.

This research proposes a microneedle patch that delivers semaglutide (a weight-loss drug) through the skin. Instead of getting a shot every week, you apply a small patch once, and it releases the medication slowly over four weeks. In rats, this worked just as well as getting four separate shots. While promising for reducing pain and improving adherence, this is still experimental technology tested only on animals, not yet available for human use.

Controlled metabolic accelerators (CMAs) like HU6 induce weight loss via increased mitochondrial energy expenditure (uncoupling) rather than caloric restriction, resulting in fat loss while sparing skeletal muscle mass in patients with obesity-related HFpEF.

This paper describes a new class of drugs (CMAs) that burn fat by speeding up metabolism rather than restricting food. In early studies, this approach reduced fat mass significantly while keeping muscle mass stable, unlike diet or surgery which often weaken patients. This trial tests if this works for heart failure patients with obesity. It is not a lifestyle intervention but a pharmaceutical one requiring medical supervision.

Precision nutrition strategies, including monitoring postprandial glycemic responses and gut microbiome composition, may attenuate unfavorable cardiovascular risk factors associated with menopause.

Consider how your body responds to specific foods after eating (postprandial response). While full precision nutrition testing may not be available, focusing on fiber, reducing sugar, and potentially incorporating isoflavone-rich foods (like soy) may support gut health and metabolic stability during menopause.

Human observational studies on MSG and obesity show inconsistent results, with some finding positive associations and others finding no association or inverse associations, largely due to measurement errors and confounding factors.

Human studies on MSG and weight are mixed. While animal studies suggest risks, human data is not conclusive. Reducing intake of processed foods with hidden MSG is a low-risk strategy for overall health.

GLP-1 agonist administration in Type 1 Diabetes patients can precipitate Euglycemic Diabetic Ketoacidosis (EDKA) by suppressing gluconeogenesis and glycogenolysis, masking the hyperglycemia typically required for DKA diagnosis.

If you have Type 1 Diabetes and are taking a GLP-1 agonist (like Wegovy or Ozempic), be aware that you can develop Diabetic Ketoacidosis (DKA) even if your blood sugar looks normal. This is called Euglycemic DKA. If you experience nausea, vomiting, or abdominal pain, do not assume it is just a side effect or that your insulin is working. Check your blood ketones and seek medical attention if they are elevated, as standard DKA treatments (high insulin, no dextrose) may be dangerous without dextrose support.

Chronic stimulation of pancreatic beta-cells by incretin agonists may lead to beta-cell exhaustion, receptor downregulation, and potentially beta-cell failure over the long term.

While generally safe, long-term use of incretin medications may theoretically stress pancreatic beta-cells. Doctors monitor for this, but the long-term human data is still being gathered. It is important to discuss any concerns about long-term safety with your healthcare provider.

Modern obesogenic environments (sedentary lifestyle, high-calorie processed food) exploit evolutionary adaptations (brain expansion, efficient fat storage) leading to a 'normalization' of obesity phenotypes and genotypes.

Your environment is shaping your biology. To combat obesity, you must actively create a 'non-obesogenic' environment (healthy food access, physical activity) because your evolutionary biology is wired to store fat in such settings.

Chronic GIPR agonism may lead to desensitization that mimics functional antagonism, potentially explaining why both agonists and antagonists result in weight loss.

There is a theoretical possibility that long-term use of GIP-activating drugs could lead to receptor desensitization, acting like a blocker. However, current clinical evidence does not strongly support this in the brain, and these drugs remain effective for weight loss. Monitor your progress with your doctor.

Unimolecular tetra-receptor agonists (TC4) simultaneously activate GLP-1R, GIPR, GcgR, and Y2R, resulting in superior metabolic efficacy (weight loss and glycemic control) compared to mono- or dual-agonists by leveraging synergistic receptor engagement.

This research describes a new class of peptide drugs that target four metabolic receptors (GLP-1, GIP, Glucagon, and PYY) simultaneously. In preclinical studies, this approach showed strong potential for treating obesity and type 2 diabetes with fewer side effects like nausea than older drugs. It is not yet available for human use.

Tirzepatide administration is associated with novel postmarketing adverse events including palpitations, musculoskeletal pain, and headaches, which were not prominent in initial clinical trials.

If you experience palpitations, muscle pain, or headaches after starting Tirzepatide, report these to your doctor. These are not the typical stomach issues and may require dose adjustment or injection site changes.

South Asian ethnicity is predisposed to 'thin-fat' obesity (normal weight obesity), leading to higher risks of diabetes, hypertension, and dyslipidemia at lower BMIs.

If you are South Asian, your risk for diabetes and heart disease starts at a lower weight than other ethnicities. Even if your BMI is normal, you might have 'thin-fat' obesity. Get regular check-ups for blood sugar, blood pressure, and cholesterol, and focus on building muscle and staying active.

Tirzepatide, a dual GLP-1/GIP receptor agonist, may modify the natural course of lipedema by targeting its underlying immunometabolic, inflammatory, and fibrotic pathophysiology, rather than solely reducing body weight.

If you have lipedema, especially with insulin resistance, talk to your doctor about tirzepatide. It’s not just for weight loss; it may help reduce the inflammation and fibrosis causing your pain and stiffness. Since it’s a newer treatment for lipedema, ask about clinical trials or off-label use if appropriate for your case.

An automatic remote weight management system using smart scales and cloud-based dashboards can effectively monitor treatment response and identify early deviations from weight trajectories without increasing patient burden.

Using a smart scale that automatically uploads data to your doctor's dashboard can help catch weight regain early without you having to do extra work. This tool helps your care team prioritize who needs help, potentially keeping you on your medication and avoiding unnecessary visits.

GLP-1 RAs are associated with an increased risk of suicidal behavior and self-harm, particularly in patients with underlying mental health vulnerabilities or dysphoria.

If you are taking Semaglutide and experience mood changes, depression, or suicidal thoughts, contact your healthcare provider immediately. Do not ignore these symptoms. Regular screening for mental health is recommended for all patients on this medication.

Creatine supplementation trends toward increasing lean muscle mass in prostate cancer patients undergoing ADT.

Creatine supplementation may help preserve lean muscle mass in prostate cancer patients on hormone therapy, though the evidence is not yet definitive. It is worth discussing with your healthcare provider as a potential supportive measure.